26 sources live Get alerts
HomeEarnings
Earnings & guidance1 min read

Merck lowers 2026 profit outlook on acquisition-related charges

The pharmaceutical company cut its full-year earnings forecast due to costs tied to its Terns Pharmaceuticals deal
WHY IT MOVED
Acquisition charges are hitting Merck's bottom line even as the company works to integrate Terns Pharmaceuticals into its portfolio.
AT PUBLICATION
MRK127.77▼ -1.87%
Measured when this story was written, not live.
MRK Terns Pharmaceuticals Earnings & guidance Deals & M&A InstantWhy Newsroom 3h ago

The numbers

Yahoo Finance reports that Merck reduced its 2026 profit forecast, citing charges related to its acquisition of Terns Pharmaceuticals. The pharmaceutical company has not independently confirmed the revised guidance. The report did not specify the size of the charge or the updated earnings range.

Why it matters

Deal-related costs typically include one-time expenses for integration, restructuring, and accounting adjustments that depress reported earnings in the near term but are excluded from the adjusted figures analysts use to value the business. Merck previously cut its profit outlook in August while raising its revenue forecast, signaling that top-line growth from new drugs was being offset by deal expenses.

How this compares

Merck lowered its full-year profit forecast on August 4 due to charges tied to the Terns acquisition, even as it raised its revenue outlook on strength in new drug sales. The company had also cut its earnings guidance earlier that same month as acquisition costs weighed on the bottom line. The Terns deal added a pipeline of treatments for metabolic diseases to Merck's portfolio, but the integration costs have repeatedly forced the company to revise its profit expectations downward.

What to watch

Investors will look for detail on the size of the charge and whether Merck's adjusted earnings guidance, which strips out one-time costs, remains intact. The company has not commented on the reported forecast cut or provided a timeline for when integration expenses will subside.

SHARE
HOW THIS STORY WAS MADE

Sources

Artificially generated from public sources, explained in our own words, and published as fast as possible. Our team holds editorial responsibility. This is analysis, not investment advice.

More stories

InstantWhy

Procter & Gamble to acquire supplements brand Thorne in health business expansion

The consumer goods giant is buying the supplements company as it pushes deeper into health and wellness, CEO S
PG THRN 2026-08-04 15:41
InstantWhy

Two charged in federal drug trafficking probe in southern Maryland

A Maryland resident and an El Salvadoran national face federal indictment following investigation by regional
✓ Official source BREAKING 2026-08-04 15:41
InstantWhy

New Jersey sues Amazon over delivery contractor practices in antitrust case

The state alleges the company's third-party delivery model harms competition and working conditions
AMZN 2026-08-04 15:18

Understand the market in five minutes a day

The free daily brief: what moved, and why it moved.

We store your email to send you the brief, nothing else. No tracking, no selling, unsubscribe in one click. Privacy policy.
We're building up to daily — you'll be among the first to get it.

We use no tracking or advertising cookies. If we ever add analytics, they stay off unless you say yes. Cookie policy